LENZ THERAPEUTICS INC (LENZ) Stock Price, Quote, News and Overview
NASDAQ:LENZ - Nasdaq - US52635N1037 - Common Stock - Currency: USD
LENZ Quote, Performance and Key Statistics
25.79
+1.68 (+6.97%)
The current stock price of LENZ is 25.79 USD. In the past month the price decreased by -3.26%. In the past year, price increased by 64.06%.
LENZ Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.41B | ||
| AMGN | AMGEN INC | 14.05 | 149.68B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.28 | 126.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.01B | ||
| ARGX | ARGENX SE - ADR | 322.51 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.80B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.55B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About LENZ
Company Profile
LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. The company is headquartered in Del Mar, California and currently employs 6 full-time employees. The company went IPO on 2021-06-25. The firm is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Company Info
LENZ THERAPEUTICS INC
445 Marine View Ave Suite 320
Del Mar CALIFORNIA US
Employees: 6
Company Website: https://lenz-tx.com/
Investor Relations: https://ir.graphitebio.com/
Phone: 18589257000
LENZ THERAPEUTICS INC / LENZ FAQ
What is the stock price of LENZ THERAPEUTICS INC today?
The current stock price of LENZ is 25.79 USD. The price increased by 6.97% in the last trading session.
What is the ticker symbol for LENZ THERAPEUTICS INC stock?
The exchange symbol of LENZ THERAPEUTICS INC is LENZ and it is listed on the Nasdaq exchange.
On which exchange is LENZ stock listed?
LENZ stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LENZ THERAPEUTICS INC stock?
14 analysts have analysed LENZ and the average price target is 43.13 USD. This implies a price increase of 67.24% is expected in the next year compared to the current price of 25.79. Check the LENZ THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LENZ THERAPEUTICS INC worth?
LENZ THERAPEUTICS INC (LENZ) has a market capitalization of 710.26M USD. This makes LENZ a Small Cap stock.
How many employees does LENZ THERAPEUTICS INC have?
LENZ THERAPEUTICS INC (LENZ) currently has 6 employees.
What are the support and resistance levels for LENZ THERAPEUTICS INC (LENZ) stock?
LENZ THERAPEUTICS INC (LENZ) has a support level at 23.71 and a resistance level at 26.49. Check the full technical report for a detailed analysis of LENZ support and resistance levels.
Should I buy LENZ THERAPEUTICS INC (LENZ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LENZ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LENZ, evaluating the profitability, health, valuation and growth aspects
- LENZ THERAPEUTICS INC (LENZ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LENZ THERAPEUTICS INC (LENZ) Sales and EPS estimates to see what analysts future expectations are.
- LENZ THERAPEUTICS INC (LENZ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LENZ THERAPEUTICS INC (LENZ) Insider and Institutional Ownership to learn about the owners and their transactions.
- LENZ THERAPEUTICS INC (LENZ) Stock Chart to make your own analysis
- LENZ THERAPEUTICS INC (LENZ) Latest news and press-releases to stay up to date.
Does LENZ THERAPEUTICS INC (LENZ) stock pay dividends?
LENZ does not pay a dividend.
When does LENZ THERAPEUTICS INC (LENZ) report earnings?
LENZ THERAPEUTICS INC (LENZ) will report earnings on 2025-05-07, after the market close.
What is the Price/Earnings (PE) ratio of LENZ THERAPEUTICS INC (LENZ)?
LENZ THERAPEUTICS INC (LENZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.77).
What is the Short Interest ratio of LENZ THERAPEUTICS INC (LENZ) stock?
The outstanding short interest for LENZ THERAPEUTICS INC (LENZ) is 9.54% of its float. Check the ownership tab for more information on the LENZ short interest.
LENZ Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to LENZ. When comparing the yearly performance of all stocks, LENZ is one of the better performing stocks in the market, outperforming 95.45% of all stocks.
LENZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LENZ. While LENZ has a great health rating, there are worries on its profitability.
LENZ Financial Highlights
Over the last trailing twelve months LENZ reported a non-GAAP Earnings per Share(EPS) of -4.77. The EPS increased by 62.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.12% | ||
| ROE | -24.39% | ||
| Debt/Equity | 0 |
LENZ Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to LENZ. The Buy consensus is the average rating of analysts ratings from 14 analysts.